MARKET

VERU

VERU

VERU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.740
+0.090
+2.47%
After Hours: 3.790 +0.05 +1.34% 16:58 05/28 EDT
OPEN
3.660
PREV CLOSE
3.650
HIGH
3.840
LOW
3.650
VOLUME
678.16K
TURNOVER
--
52 WEEK HIGH
4.740
52 WEEK LOW
1.670
MARKET CAP
243.82M
P/E (TTM)
-24.2228
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VERU stock price target is 8.50 with a high estimate of 13.00 and a low estimate of 6.00.

EPS

VERU News

More
Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd
GlobeNewswire · 2d ago
Veru Inc. (NASDAQ:VERU) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Simply Wall St. · 05/15 17:39
Oppenheimer Maintains Outperform on Veru, Raises Price Target to $9
Oppenheimer maintains Veru (NASDAQ:VERU) with a Outperform and raises the price target from $8 to $9.
Benzinga · 05/14 12:56
75 Biggest Movers From Yesterday
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares climbed 88% to close at $4.14 on Wednesday following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/14 08:26
Veru Inc. (VERU) CEO Mitchell Steiner on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/13 20:02
Veru Inc. (VERU) Q2 2020 Earnings Call Transcript
VERU earnings call for the period ending March 31, 2020.
Motley Fool · 05/13 19:30
Mid-Afternoon Market Update: Varex Imaging Falls After Q2 Results; Aviat Networks Shares Climb
Toward the end of trading Wednesday, the Dow traded down 2.3% to 23,217 while the NASDAQ fell 2.08% to 8,815. The S&P also fell, dropping 2.14% to 2,808.
Benzinga · 05/13 18:35
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares jumped 117% to $4.7799 following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/13 16:41

Industry

Pharmaceuticals
+1.28%
Pharmaceuticals & Medical Research
+1.04%

Hot Stocks

Symbol
Price
%Change

About VERU

Veru Inc. is an oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals. Its oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase II clinical trial for the treatment of hot flashes in men, and VERU-100, which is a gonadotropin-releasing hormone (GnRH) antagonist. Its urology specialty pharmaceutical drug candidate is Tadalafil and Finasteride Combination (TADFIN), which is a tadalafil and finasteride combination oral capsule for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal Condom for prevention of pregnancy and sexually transmitted infections, and PREBOOST wipes for the prevention of premature ejaculation.
More

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.